BlackRock Inc. bought a new stake in shares of Invivyd, Inc. (NASDAQ:IVVD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 16,134,885 shares of the company's stock, valued at approximately $14,076,000. BlackRock Inc. owned approximately 5.48% of Invivyd as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in IVVD. Janus Henderson Group PLC increased its position in shares of Invivyd by 1.7% during the first quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company's stock valued at $42,857,000 after buying an additional 551,188 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Invivyd during the 4th quarter worth approximately $53,809,000. BVF Inc. IL bought a new position in shares of Invivyd in the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. purchased a new position in shares of Invivyd in the 3rd quarter valued at approximately $18,831,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Invivyd during the third quarter valued at approximately $8,108,000. Institutional investors own 70.36% of the company's stock.
Invivyd Price Performance
Invivyd stock opened at $0.83 on Friday. Invivyd, Inc. has a one year low of $0.53 and a one year high of $3.07. The business's fifty day moving average is $0.78 and its 200 day moving average is $1.17. The stock has a market capitalization of $246.12 million, a PE ratio of -2.53 and a beta of 0.81.
Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. As a group, sell-side analysts expect that Invivyd, Inc. will post -0.51 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Jill Andersen sold 37,256 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $26,824.32. Following the sale, the insider owned 314,480 shares in the company, valued at approximately $226,425.60. This trade represents a 10.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 228,024 shares of company stock worth $176,540 in the last 90 days. 12.25% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of research firms have issued reports on IVVD. Cantor Fitzgerald reiterated an "overweight" rating on shares of Invivyd in a report on Thursday, August 27th. HC Wainwright reiterated a "buy" rating on shares of Invivyd in a research note on Tuesday, August 18th. BTIG Research reissued a "buy" rating on shares of Invivyd in a research note on Tuesday, July 7th. Weiss Ratings cut shares of Invivyd from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, August 24th. Finally, Wall Street Zen lowered shares of Invivyd from a "hold" rating to a "strong sell" rating in a report on Saturday, May 16th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Invivyd presently has a consensus rating of "Hold" and an average price target of $8.00.
View Our Latest Stock Report on IVVD
Invivyd Company Profile
(
Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Featured Articles
Want to see what other hedge funds are holding IVVD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invivyd, Inc. (NASDAQ:IVVD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
